Viewing Study NCT00698451

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:51 PM
Ignite Modification Date: 2026-01-09 @ 12:25 PM
Study NCT ID: NCT00698451
Status: COMPLETED
Last Update Posted: 2013-09-06
First Post: 2008-06-12
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Neoplasms View
None Fallopian Tube Neoplasms View
None Peritoneal Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Ovarian cancer View
None fallopian tube cancer View
None primary peritoneal cancer View
None DOXIL View
None carboplatin View
None bevacizumab View